Moderna, Inc. $MRNA Position Increased by Ritholtz Wealth Management

Ritholtz Wealth Management lifted its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 162.7% during the third quarter, Holdings Channel reports. The institutional investor owned 9,001 shares of the company’s stock after buying an additional 5,575 shares during the quarter. Ritholtz Wealth Management’s holdings in Moderna were worth $1,733,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Costello Asset Management INC lifted its position in Moderna by 7.3% during the third quarter. Costello Asset Management INC now owns 966 shares of the company’s stock valued at $186,000 after acquiring an additional 66 shares during the last quarter. Physician Wealth Advisors Inc. boosted its stake in Moderna by 8.3% in the third quarter. Physician Wealth Advisors Inc. now owns 886 shares of the company’s stock valued at $171,000 after acquiring an additional 68 shares in the last quarter. Fortitude Family Office LLC boosted its stake in Moderna by 53.1% in the third quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock valued at $43,000 after acquiring an additional 77 shares in the last quarter. Lido Advisors LLC grew its holdings in Moderna by 0.5% in the third quarter. Lido Advisors LLC now owns 16,605 shares of the company’s stock worth $3,198,000 after purchasing an additional 83 shares during the last quarter. Finally, TD Waterhouse Canada Inc. grew its holdings in Moderna by 2.6% in the second quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock worth $246,000 after purchasing an additional 85 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

MRNA opened at $223.37 on Monday. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $280.80. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. The company has a market cap of $90.38 billion, a P/E ratio of -31.46 and a beta of 1.16. The firm’s 50-day moving average price is $201.67 and its 200-day moving average price is $96.41.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($1.10) by $1.48. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. Moderna’s revenue was up 29.2% on a year-over-year basis. During the same period last year, the firm posted ($0.51) EPS. As a group, equities analysts anticipate that Moderna, Inc. will post -5.14 EPS for the current fiscal year.

Recent Moderna Headlines

Here are a few of the latest headlines about MRNA:

  • Positive Sentiment: Moderna lifted its 2026 revenue-growth forecast to 15%–25%, from a previous outlook of up to 10%, citing commercial progress including stronger overseas COVID-19 sales. Article
  • Positive Sentiment: The company highlighted progress in its oncology pipeline, including its personalized cancer vaccine, positioning cancer treatments as a potential longer-term growth driver. Article
  • Neutral Sentiment: Moderna is scheduled to join the MSCI World Index in November, which could broaden its investor reach. It also reported peer-reviewed real-world data on its mNEXSPIKE COVID-19 vaccine in older adults; the reports provided limited detail on the potential commercial impact. Article

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 34,836 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 39,145 shares of Moderna stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the sale, the president owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. The trade was a 2.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 197,251 shares of company stock valued at $33,875,904. Insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the topic of a number of recent analyst reports. UBS Group reaffirmed a “neutral” rating on shares of Moderna in a research report on Tuesday, September 22nd. TD Cowen reiterated a “buy” rating on shares of Moderna in a report on Wednesday, October 21st. Wolfe Research raised Moderna from an “underperform” rating to a “peer perform” rating in a research report on Tuesday, August 25th. Bank of America raised their price objective on Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Finally, Berenberg Bank boosted their target price on Moderna from $45.00 to $100.00 and gave the stock a “hold” rating in a research note on Friday, September 11th. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, Moderna currently has an average rating of “Hold” and an average target price of $113.75.

Check Out Our Latest Stock Analysis on MRNA

Moderna Company Profile

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Recommended Stories

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.